Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressants Should Not Be Used Off-Label In Children, EMEA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

European Medicines Agency recommends that warnings highlighting the increased risk of suicidal behavior should be included in product information for SSRIs/SNRIs. If the products are used off-label in pediatric populations out of clinical necessity, children should be monitored for suicidal behavior, the agency says.
Advertisement

Related Content

Prozac Pediatric Indication Recommended By EU Committee
Prozac Pediatric Indication Recommended By EU Committee
Antidepressant MedGuide Distribution Imminent; Unit-Of-Use Packs To Follow
Antidepressant MedGuide Distribution Imminent; Unit-Of-Use Packs To Follow

Topics

Advertisement
UsernamePublicRestriction

Register

PS062067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel